Press Release 2023. 09. 23

Innorna Receives IND Clearance by FDA Enabling Phase I Initiation for Herpes Zoster mRNA Vaccine

HONGKONG, SHENZHEN, NANJING, CHINA, Sept. 23, 2023—Innorna, a clinical-stage biotech company pioneering its proprietary lipid nanoparticle (LNP) technology to develop novel RNA therapeutics, announces that its herpes zoster (HZ) IN001 mRNA Vaccine has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance. This is the third HZ mRNA vaccine worldwide to gain FDA IND clearance using mRNA-LNP technology following Moderna and Pfizer/BioNTech.


About Herpes Zoster and IN001

HZ, also known as shingles, is a disease caused by reactivation of the varicella-zoster virus (VZV), which typically occurs in adults or elderly. With an aging global population, a next-generation HZ vaccine with comparable or higher effectiveness, improved safety profile and simpler manufacturing process can improve the vaccine accessibility and help address this important global health priority. IN001 is a mRNA vaccine designed for preventing HZ, with a nucleoside-modified mRNA expressing the glycoprotein E of VZV and an LNP delivery system specially designed for vaccines. The preclinical study of IN001 has demonstrated strong boost of both humoral and cellular immunity with a good safety profile in animals.



About Innorna

Innorna was founded in 2019, focusing on developing best-in-class LNP delivery technology and advancing innovative RNA therapies to address unmet medical needs globally. Innorna has built a diversity-oriented lipid library (DOLL) of over 5,000 ionizable lipids, which can be applied in various modalities or scenarios, including mRNA vaccines and drugs, genome editing therapies, and cell therapies, among others. Based on its proprietary mRNA and LNP technology platform, Innorna has built several internal R&D pipelines in the areas of infectious disease and rare disease. Meanwhile, the company has established partnerships with pharma and biotech to explore the potential of the technology in broader therapeutic areas. Since its establishment more than three years ago, Innorna has been widely recognized by the investment community and industry. It has won dozens of awards including MIT Technology Review's Global 50 Smartest Companies and Fortune China 's Most Socially Influential Startups. Visit Innorna's website at for more information.